NAV

Tiletamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tiletamine
DrugBank Accession Number
DB11549
Background

This drug is a dissociative anesthetic agent that falls under the drug category of NMDA receptor antagonists. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

Type
Small Molecule
Groups
Vet approved
Structure
3D
Similar Structures
Weight
Average: 223.33
Monoisotopic: 223.103085345
Chemical Formula
C12H17NOS
Synonyms
  • Tiletamine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Tiletamine is combined with 1,2-Benzodiazepine.
AcetazolamideThe risk or severity of CNS depression can be increased when Acetazolamide is combined with Tiletamine.
AcetophenazineThe risk or severity of CNS depression can be increased when Acetophenazine is combined with Tiletamine.
AgomelatineThe risk or severity of CNS depression can be increased when Agomelatine is combined with Tiletamine.
AlfentanilThe risk or severity of CNS depression can be increased when Alfentanil is combined with Tiletamine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Tiletamine hydrochloride99TAQ2QWJI14176-50-2ZUYKJZQOPXDNOK-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Thiophenes / Heteroaromatic compounds / Cyclic ketones / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aralkylamine / Aromatic heteromonocyclic compound / Carbonyl group / Cyclic ketone / Heteroaromatic compound / Hydrocarbon derivative / Ketone / Organic oxide / Organic oxygen compound / Organoheterocyclic compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
2YFC543249
CAS number
14176-49-9
InChI Key
QAXBVGVYDCAVLV-UHFFFAOYSA-N
InChI
InChI=1S/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3
IUPAC Name
2-(ethylamino)-2-(thiophen-2-yl)cyclohexan-1-one
SMILES
CCNC1(CCCCC1=O)C1=CC=CS1

References

General References
  1. Natalini CC, Alves SD, Guedes AG, Polydoro AS, Brondani JT, Bopp S: Epidural administration of tiletamine/zolazepam in horses. Vet Anaesth Analg. 2004 Apr;31(2):79-85. [Article]
  2. Wilson RP, Zagon IS, Larach DR, Lang CM: Cardiovascular and respiratory effects of tiletamine-zolazepam. Pharmacol Biochem Behav. 1993 Jan;44(1):1-8. [Article]
  3. Calderwood HW, Klide AM, Cohn BB, Soma LR: Cardiorespiratory effects of tiletamine in cats. Am J Vet Res. 1971 Oct;32(10):1511-5. [Article]
  4. Hubbell JA, Bednarski RM, Muir WW: Xylazine and tiletamine-zolazepam anesthesia in horses. Am J Vet Res. 1989 May;50(5):737-42. [Article]
  5. Cattet MR, Caulkett NA, Lunn NJ: Anesthesia of polar bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine. J Wildl Dis. 2003 Jul;39(3):655-64. [Article]
  6. Lin HC, Wallace SS, Tyler JW, Robbins RL, Thurmon JC, Wolfe DF: Comparison of tiletamine-zolazepam-ketamine and tiletamine-zolazepam-ketamine-xylazine anaesthesia in sheep. Aust Vet J. 1994 Aug;71(8):239-42. [Article]
  7. Fernandez-Moran J, Palomeque J, Peinado VI: Medetomidine/tiletamine/zolazepam and xylazine/tiletamine/zolazepam combinations for immobilization of fallow deer (Cervus dama). J Zoo Wildl Med. 2000 Mar;31(1):62-4. [Article]
  8. Caulkett NA, Cattet MR, Cantwell S, Cool N, Olsen W: Anesthesia of wood bison with medetomidine-zolazepam/tiletamine and xylazine-zolazepam/tiletamine combinations. Can Vet J. 2000 Jan;41(1):49-53. [Article]
  9. Selmi AL, Mendes GM, Figueiredo JP, Guimaraes FB, Selmi GR, Bernal FE, McMannus C, Paludo GR: Chemical restraint of peccaries with tiletamine/zolazepam and xylazine or tiletamine/zolazepam and butorphanol. Vet Anaesth Analg. 2003 Jan;30(1):24-9. [Article]
  10. Cattet MR, Caulkett NA, Polischuk SC, Ramsay MA: Anesthesia of polar bears (Ursus maritimus) with zolazepam-tiletamine, medetomidine-ketamine, and medetomidine-zolazepam-tiletamine. J Zoo Wildl Med. 1999 Sep;30(3):354-60. [Article]
KEGG Drug
D08596
ChemSpider
24714
RxNav
1535217
ChEBI
94356
ChEMBL
CHEMBL2110703
Wikipedia
Tiletamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntramuscular; Intravenous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0965 mg/mLALOGPS
logP2.58ALOGPS
logP3.01Chemaxon
logS-3.4ALOGPS
pKa (Strongest Acidic)18.69Chemaxon
pKa (Strongest Basic)7.56Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area29.1 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity62.39 m3·mol-1Chemaxon
Polarizability24.65 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0frl-0900000000-90b59ece6e6661f5772f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0190000000-730e07aed74fb21fcfc6
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-1390000000-b2269270af99f119e56a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01vk-5930000000-21c58018ba64bd290fdd
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004j-9720000000-abbbf3edb81d4cc77f79
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-2900000000-b6f916eea236441b672d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01q9-6900000000-c11a5b7b785a649e2d35
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-151.50493
predicted
DeepCCS 1.0 (2019)
[M+H]+153.86293
predicted
DeepCCS 1.0 (2019)
[M+Na]+161.92792
predicted
DeepCCS 1.0 (2019)

Drug created at February 26, 2016 17:43 / Updated at February 21, 2021 18:53